February 2026 in “Pharmaceuticals” KRDQN effectively predicts adverse drug reactions with high accuracy and clear explanations.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ixekizumab may be an effective first treatment for a rare skin condition causing hair loss.
March 2026 in “Mendeley Data” rwSALT accurately measures hair regrowth in alopecia areata using scalp photos.
10 citations
,
May 2020 in “Dermatologic therapy” Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.
2 citations
,
June 2024 in “Dermatology” Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
13 citations
,
August 2000 in “Blood” Measuring minimal residual disease on day 15 helps identify high-risk leukemia patients.
1 citations
,
November 2024 in “Saudi Pharmaceutical Journal” Adding baricitinib will increase costs but offers more treatment options for alopecia areata.
January 2026 in “International Journal of Applied Pharmaceutics” The method accurately measures Minoxidil in drugs and is reliable for routine use.
January 2013 in “Annals of King Edward Medical University” Androgenetic alopecia negatively impacts quality of life, especially for women, due to social reactions.
9 citations
,
January 2023 in “Journal of Clinical Medicine” The FFA-QLI is a reliable tool for assessing quality of life in women with severe Frontal Fibrosing Alopecia.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The model improves understanding of androgen interactions by focusing on signal intensity and system capacity.
5 citations
,
April 2019 in “Phytochemical Analysis” The new ELISA method is reliable and eco-friendly for checking the quality of Pueraria candollei.
13 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
2 citations
,
March 2025 in “ESMO Open” Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.
2 citations
,
January 2007 in “Toxicologie Analytique et Clinique” A woman survived a massive lithium overdose that caused a form of hair loss.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
June 2020 in “Journal of Investigative Dermatology” FDA-cleared devices often fail to produce high-quality platelet-rich plasma consistently.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
January 2011 in “Nuclear Techniques” Lead levels in hair increased due to environmental exposure, while iron, copper, and zinc levels stayed stable.
November 2025 in “Informatica” The method greatly improves low-light sports images' quality and reduces artifacts.
2 citations
,
May 2021 in “Neuropathology & applied neurobiology/Neuropathology and applied neurobiology” Correct diagnosis and treatment are crucial for effective management of lipid storage myopathies.
11 citations
,
March 2023 in “Frontiers in Nutrition” Hair analysis can detect small changes in dietary zinc intake.
May 2025 in “Immunotherapy” Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.
IVL-DrugFluidic® can mass-produce high-quality, long-acting injectable drug microspheres, improving patient compliance and reducing side effects.
July 1997 in “The Lancet” Finasteride increased hair count and regrowth in men with hair loss but also caused more sexual side effects than placebo.
54 citations
,
November 2014 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Combining LFQS and IPL is more effective and faster for treating melasma than LFQS alone.
July 2025 in “Anais Brasileiros de Dermatologia” The Brazilian version of the Alopecia Areata Quality of Life Index is reliable for assessing patients' quality of life.
November 2025 in “Reumatismo” The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.
March 1986 in “Fed. Proc., Fed. Am. Soc. Exp. Biol.; (United States)” Marginal dietary zinc intake in rats led to weight loss and hair issues, but no significant changes in blood fractions.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.